Testimony Before the FDA’s Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee Regarding Celecoxib

April 25, 2018

View as PDF

In testimony before a meeting of the Food and Drug Administration’s (FDA’s) Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee, Public Citizen argued that because of the major limitations of the PRECISION trial, no meaningful conclusions can be drawn from the trial regarding the cardiovascular safety of celecoxib relative to ibuprofen and naproxen.